MEDROL- methylprednisolone tablet

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Wirkstoff:

METHYLPREDNISOLONE (UNII: X4W7ZR7023) (METHYLPREDNISOLONE - UNII:X4W7ZR7023)

Verfügbar ab:

Zoetis Inc.

INN (Internationale Bezeichnung):

METHYLPREDNISOLONE

Zusammensetzung:

METHYLPREDNISOLONE 4 mg

Verabreichungsweg:

ORAL

Verschreibungstyp:

PRESCRIPTION

Anwendungsgebiete:

The indications for MEDROL Tablets are the same as those for other anti-inflammatory steroids and comprise the various collagen, dermal, allergic, ocular, otic, and musculoskeletal conditions known to be responsive to the anti-inflammatory corticosteroids. Representative of the conditions in which the use of steroid therapy and the benefits to be derived therefrom have had repeated confirmation in the veterinary literature are: (1) dermal conditions, such as non-specific eczema, summer dermatitis, and burns; (2) allergic manifestations, such as acute urticaria, allergic dermatitis, drug and serum reactions, bronchial asthma, and pollen sensitivities; (3) ocular conditions, such as iritis, iridocyclitis, secondary glaucoma, uveitis, and chorioretinitis; (4) otic conditions, such as otitis externa; (5) musculoskeletal conditions, such as myositis, rheumatoid arthritis, osteoarthritis, and bursitis; (6) various chronic or recurrent diseases of unknown etiology such as ulcerative colitis and nephrosis. In acute a

Produktbesonderheiten:

Veterinary MEDROL Tablets are compressed cross-scored tablets available in bottles of 500. Each 4 mg tablet contains 4 mg methylprednisolone. Store at controlled room temperature 20° to 25° C (68° to 77° F).

Berechtigungsstatus:

New Animal Drug Application

Fachinformation

MEDROL- METHYLPREDNISOLONE TABLET
ZOETIS INC.
----------
MEDROL
Medrol®
(methylprednisolone tablets)
FOR ORAL USE IN DOGS AND CATS
CAUTION: Federal law restricts this drug to use by or on the order of
a licensed
veterinarian.
DESCRIPTION
Methylprednisolone, a potent anti-inflammatory steroid synthesized and
developed in the
Research Laboratories of The Upjohn Company is the 6-methyl derivative
of
prednisolone. It has a greater anti-inflammatory potency than
prednisolone and even
less tendency than prednisolone to induce sodium and water retention.
Its advantage
over the older corticoids lies in its ability to achieve equal
anti-inflammatory effect with
lower dose, while at the same time enhancing the split between
anti-inflammatory and
mineralocorticoid activities.
INDICATIONS
The indications for MEDROL Tablets are the same as those for other
anti-inflammatory
steroids and comprise the various collagen, dermal, allergic, ocular,
otic, and
musculoskeletal conditions known to be responsive to the
anti-inflammatory
corticosteroids. Representative of the conditions in which the use of
steroid therapy and
the benefits to be derived therefrom have had repeated confirmation in
the veterinary
literature are: (1) dermal conditions, such as non-specific eczema,
summer dermatitis,
and burns; (2) allergic manifestations, such as acute urticaria,
allergic dermatitis, drug
and serum reactions, bronchial asthma, and pollen sensitivities; (3)
ocular conditions,
such as iritis, iridocyclitis, secondary glaucoma, uveitis, and
chorioretinitis; (4) otic
conditions, such as otitis externa; (5) musculoskeletal conditions,
such as myositis,
rheumatoid arthritis, osteoarthritis, and bursitis; (6) various
chronic or recurrent
diseases of unknown etiology such as ulcerative colitis and nephrosis.
In acute adrenal insufficiency, MEDROL may be effective because of its
ability to correct
the defect in carbohydrate metabolism and relieve the impaired
diuretic response to
water characteristic of primary or secondary adrenal insufficiency.
How